WallStSmart

Aclaris Therapeutics Inc (ACRS)vsRevolution Medicines Inc (RVMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Aclaris Therapeutics Inc generates 1008% more annual revenue ($8.22M vs $742,000). RVMD leads profitability with a 0.0% profit margin vs 0.0%. RVMD earns a higher WallStSmart Score of 24/100 (F).

ACRS

Avoid

20

out of 100

Grade: F

Growth: 2.7Profit: 2.5Value: 6.7Quality: 5.3
Piotroski: 3/9Altman Z: -7.73

RVMD

Avoid

24

out of 100

Grade: F

Growth: 3.7Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 1/9Altman Z: -0.99
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ACRSUndervalued (+47.8%)

Margin of Safety

+47.8%

Fair Value

$6.49

Current Price

$5.32

$1.17 discount

UndervaluedFair: $6.49Overvalued

Intrinsic value data unavailable for RVMD.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ACRS0 strengths · Avg: 0/10

No standout strengths identified

RVMD1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.259/10

Conservative balance sheet, low leverage

Areas to Watch

ACRS4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$818.43M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

RVMD4 concerns · Avg: 3.5/10
Price/BookValuation
16.1x4/10

Trading at 16.1x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

Comparative Analysis Report

WallStSmart Research

Bull Case : ACRS

ACRS has a balanced fundamental profile.

Bull Case : RVMD

The strongest argument for RVMD centers on Debt/Equity.

Bear Case : ACRS

The primary concerns for ACRS are EPS Growth, Market Cap, Profit Margin.

Bear Case : RVMD

The primary concerns for RVMD are Price/Book, EPS Growth, Profit Margin.

Key Dynamics to Monitor

RVMD carries more volatility with a beta of 1.41 — expect wider price swings.

ACRS is growing revenue faster at -8.3% — sustainability is the question.

ACRS generates stronger free cash flow (-20M), providing more financial flexibility.

Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.

Bottom Line

RVMD scores higher overall (24/100 vs 20/100). ACRS offers better value entry with a 47.8% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Aclaris Therapeutics Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a line of novel small molecule therapeutics to address the needs of patients with immuno-inflammatory diseases. The company is headquartered in Wayne, Pennsylvania.

Visit Website →

Revolution Medicines Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.

Want to dig deeper into these stocks?